Table 1

 Comparison of ventricular remodelling and haemodynamic variables at baseline and at the end of the study between the carvedilol and placebo groups

Baseline6 Monthsp Value, baseline differencesEffect over timep Value, within group changes (95% CI)p Value, between groups changes over time (95% CI)
Values are mean (SD).
*Carvedilol group, n = 16; placebo group, n = 13.
BP, blood pressure; BSA, body surface area; LVEDVI, left ventricular end diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end systolic volume index; LVMI, left ventricular mass index; LVSVI, left ventricular stroke volume index; →, no effect over time; ↑, increase over time; ↓, decrease over time.
LVEDVI (ml/m2)Carvedilol*139 (46)131 (46)NS0.001 (3.5 to 12.8)0.05 (−0.3 to14.6)
Placebo*130 (43)130 (39)NS (−6 to 7.5)
LVESVI (ml/m2)Carvedilol100 (48)91 (45)NS0.0004 (4.8 to 13.0)0.0004 (5.9 to18.2)
Placebo89 (34)92 (37)NS (−7.8 to 1.7)
LVSVI (ml/m2)Carvedilol39 (9)40 (7)NSNS (−6.8 to 3)NS
Placebo41 (13)36 (8)NS (−1.3 to 9.6)
LVEF (%)Carvedilol31 (13)34 (13)NS0.008 (−5 to −0.80.003 (−8.5 to −1.9)
Placebo32 (10)30 (10)NS (−0.6 to 5.2)
LVMI (g/m2)Carvedilol77 (23)77 (18)NSNS (−6.8 to 8)NS
Placebo91 (24)89 (29)NS (−5.6 to 10.9)
Heart rate (beats/min)Carvedilol80 (13)74 (14)NSNS (−2.2 to 14.0)NS
Placebo84 (8)80 (12)NS (−5 to 11)
BP systolic (mm Hg)Carvedilol121 (18)116 (13)NSNS (−1.2 to 11)NS
Placebo127 (20)121 (14)NS (−2.3 to 15)
BP diastolic (mm Hg)Carvedilol74 (13)73 (12)NSNS (−3.0 to 6.7)NS
Placebo70 (13)73 (9)NS (−3.0 to 14.6)
BSA (m2)Carvedilol1.8 (0.1)2.0 (0.2)NSNS (−0.01 to 0.02)NS
Placebo1.8 (0.2)1.8 (0.1)NS (−0.07 to 0.02)